调节性B细胞
免疫疗法
医学
癌症研究
癌症
免疫学
细胞毒性T细胞
免疫系统
癌症免疫疗法
CD8型
癌细胞
抗体
B细胞
生物
内科学
生物化学
体外
作者
Enkui Zhang,Chengsheng Ding,Shuchun Li,Xueliang Zhou,Batuer Aikemu,Xiaodong Fan,Jing Sun,Min Zheng,Xia Yang
标识
DOI:10.1186/s40364-023-00460-1
摘要
Immune checkpoint inhibitors (ICIs) targeting PD-1 or PD-L1 have emerged as a revolutionary treatment strategy for human cancer patients. However, as the response rate to ICI therapy varies widely among different types of tumours, we are beginning to gain insight into the mechanisms as well as biomarkers of therapeutic response and resistance. Numerous studies have highlighted the dominant role of cytotoxic T cells in determining the treatment response to ICIs. Empowered by recent technical advances, such as single-cell sequencing, tumour-infiltrating B cells have been identified as a key regulator in several solid tumours by affecting tumour progression and the response to ICIs. In the current review, we summarized recent advances regarding the role and underlying mechanisms of B cells in human cancer and therapy. Some studies have shown that B-cell abundance in cancer is positively associated with favourable clinical outcomes, while others have indicated that they are tumour-promoting, implying that the biological function of B cells is a complex landscape. The molecular mechanisms involved multiple aspects of the functions of B cells, including the activation of CD8+ T cells, the secretion of antibodies and cytokines, and the facilitation of the antigen presentation process. In addition, other crucial mechanisms, such as the functions of regulatory B cells (Bregs) and plasma cells, are discussed. Here, by summarizing the advances and dilemmas of recent studies, we depicted the current landscape of B cells in cancers and paved the way for future research in this field.
科研通智能强力驱动
Strongly Powered by AbleSci AI